Anna B. Halpern

1.5k total citations
74 papers, 907 citations indexed

About

Anna B. Halpern is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Anna B. Halpern has authored 74 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Hematology, 30 papers in Genetics and 25 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Anna B. Halpern's work include Acute Myeloid Leukemia Research (42 papers), Acute Lymphoblastic Leukemia research (22 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers). Anna B. Halpern is often cited by papers focused on Acute Myeloid Leukemia Research (42 papers), Acute Lymphoblastic Leukemia research (22 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers). Anna B. Halpern collaborates with scholars based in United States, South Africa and Spain. Anna B. Halpern's co-authors include Roland B. Walter, Elihu H. Estey, Megan Othus, Frederick R. Appelbaum, Jerald P. Radich, Daisuke Araki, Yi Zhou, Brent L. Wood, Marco Mielcarek and Gary H. Lyman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Anna B. Halpern

61 papers receiving 898 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna B. Halpern United States 14 674 285 220 216 216 74 907
Jean Henri Bourhis France 13 1.2k 1.8× 278 1.0× 232 1.1× 179 0.8× 328 1.5× 28 1.3k
Gladstone Airewele United States 13 511 0.8× 254 0.9× 223 1.0× 246 1.1× 124 0.6× 34 865
Antônio Vaz de Macedo Brazil 12 608 0.9× 282 1.0× 214 1.0× 167 0.8× 80 0.4× 38 757
Filippo Ballerini Italy 14 662 1.0× 162 0.6× 232 1.1× 224 1.0× 245 1.1× 55 825
Rainer Krahl Germany 14 754 1.1× 195 0.7× 250 1.1× 350 1.6× 106 0.5× 42 868
ZiYi Lim United Kingdom 10 633 0.9× 144 0.5× 158 0.7× 194 0.9× 125 0.6× 28 784
Avinash G. Dinmohamed Netherlands 14 274 0.4× 127 0.4× 96 0.4× 203 0.9× 221 1.0× 62 633
DW Beelen Germany 14 750 1.1× 171 0.6× 113 0.5× 142 0.7× 178 0.8× 18 877
Munir Shahjahan United States 11 1.2k 1.8× 555 1.9× 148 0.7× 182 0.8× 295 1.4× 19 1.4k
Brian McClune United States 15 750 1.1× 278 1.0× 213 1.0× 121 0.6× 323 1.5× 68 998

Countries citing papers authored by Anna B. Halpern

Since Specialization
Citations

This map shows the geographic impact of Anna B. Halpern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna B. Halpern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna B. Halpern more than expected).

Fields of papers citing papers by Anna B. Halpern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna B. Halpern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna B. Halpern. The network helps show where Anna B. Halpern may publish in the future.

Co-authorship network of co-authors of Anna B. Halpern

This figure shows the co-authorship network connecting the top 25 collaborators of Anna B. Halpern. A scholar is included among the top collaborators of Anna B. Halpern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna B. Halpern. Anna B. Halpern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raychaudhuri, Suravi, Kevin K. Chung, Jeffrey S. McLean, et al.. (2025). Distal gut colonization by oral bacteria during intensive chemotherapy: direct evidence from strain-level analysis of paired samples. npj Biofilms and Microbiomes. 11(1). 88–88.
2.
3.
Gangat, Naseema, James M. Foran, Anna B. Halpern, et al.. (2024). A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia. Blood. 144(Supplement 1). 657–657. 3 indexed citations
4.
McLean, John S., et al.. (2024). Balancing Inpatient and Outpatient Oncology Care. Journal of the National Comprehensive Cancer Network. 22(Supplement).
5.
Appelbaum, Jacob, Kathryn Russell, Xueyan Chen, et al.. (2024). Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6517–6517.
6.
Watts, Justin M., Alessandro M. Vannucchi, Anthony M. Hunter, et al.. (2024). Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.. Journal of Clinical Oncology. 42(16_suppl). 6576–6576. 1 indexed citations
7.
Gangat, Naseema, James M. Foran, Anna B. Halpern, et al.. (2024). A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia. Clinical Lymphoma Myeloma & Leukemia. 24. S201–S201. 1 indexed citations
8.
Milano, Filippo, Brenda M. Sandmaier, Mary‐Elizabeth M. Percival, et al.. (2024). CLAG-M or FLAG-Ida Followed Immediately By Allogeneic Hematopoietic Cell Transplantation for Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm. Blood. 144(Supplement 1). 265–265.
9.
Othus, Megan, Anna B. Halpern, Jacob Appelbaum, et al.. (2023). Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents. Leukemia & lymphoma. 64(5). 990–996. 1 indexed citations
10.
Lindsay, Julian, Carla S. Walti, Anna B. Halpern, et al.. (2023). Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms. Blood Advances. 7(13). 3140–3145. 3 indexed citations
11.
Cassaday, Ryan D., Olga Sala‐Torra, Philip A. Stevenson, et al.. (2023). Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Leukemia & lymphoma. 64(5). 927–937. 4 indexed citations
12.
Othus, Megan, Mohamed L. Sorror, Anna B. Halpern, et al.. (2022). Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia. 37(1). 231–234. 4 indexed citations
13.
Halpern, Anna B., Megan Othus, Nicholas P. Howard, et al.. (2021). Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. Leukemia & lymphoma. 63(1). 142–151. 2 indexed citations
14.
Woo, Janghee, Dae Ro Choi, Barry E. Storer, et al.. (2019). Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia. Haematologica. 105(3). 652–660. 17 indexed citations
15.
Gardner, Kelda M., Anna B. Halpern, Emily M. Huebner, et al.. (2019). Need for routine examination of left ventricular ejection fraction in patients with AML. Leukemia. 34(4). 1169–1171. 2 indexed citations
16.
Buckley, Sarah, Mary‐Elizabeth M. Percival, Megan Othus, et al.. (2018). A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leukemia & lymphoma. 60(4). 1023–1029. 2 indexed citations
17.
Halpern, Anna B., Megan Othus, Emily M. Huebner, et al.. (2018). Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 32(11). 2352–2362. 34 indexed citations
18.
19.
Araki, Daisuke, Brent L. Wood, Megan Othus, et al.. (2015). Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?. Journal of Clinical Oncology. 34(4). 329–336. 258 indexed citations
20.
Odenike, Olatoyosi, Anna B. Halpern, Lucy A. Godley, et al.. (2014). A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational New Drugs. 33(2). 371–379. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean Henri Bourhis Breakdown of academic impact, for papers by Gladstone Airewele Breakdown of academic impact, for papers by Antônio Vaz de Macedo Breakdown of academic impact, for papers by Filippo Ballerini Breakdown of academic impact, for papers by Rainer Krahl Breakdown of academic impact, for papers by ZiYi Lim Breakdown of academic impact, for papers by Avinash G. Dinmohamed Breakdown of academic impact, for papers by DW Beelen Breakdown of academic impact, for papers by Munir Shahjahan Breakdown of academic impact, for papers by Brian McClune
Rankless by CCL
2026